Correvio Pharma (CORV) Tops Q1 EPS by 31c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Correvio Reports Second Quarter 2018 Financial Results
August 14, 2018 4:00 PM EDTManagement to Host Conference Call and Webcast Today, August 14, 2018 at 4:30 p.m. Eastern (1:30 p.m. Pacific)
NASDAQ: CORVÂ TSX: CORV
VANCOUVER, Aug. 14, 2018 /PRNewswire/ -Â Correvio Pharma Corp. (NASDAQ: CORV) (TSX: CORV), a revenue-generating, specialty pharmaceutical company focused on commercializing hospital drugs, today reported financial results for its second quarter ended June 30, 2018 and commented on recent accomplishments and plans.
"The first half of 2018 was marked by several important achievements, including the confirmed ability to resubmit the Brinavess® (vernakalant... More
